Precision hormone therapy: identification of positive responders

References

• Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337–42
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256–61
   PubMed Web of Science ®Google Scholar
• Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288:2123–9
   PubMed Web of Science ®Google Scholar
• Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429–32
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213–17
   PubMed Web of Science ®Google Scholar
• Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology 1997;48:1517–21
   PubMed Web of Science ®Google Scholar
• Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 2012;79:1846–52
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Henderson VW, Paine BJ, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause 2006;13:28–36
   PubMed Web of Science ®Google Scholar
• Henderson VW, Benke K, Green R, MIRAGE Study Group, et al. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 2005;76:103–5
   PubMed Web of Science ®Google Scholar
• Maki PM, Zonderman AB, Resnick SM. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry 2001;158:227–33
   PubMed Web of Science ®Google Scholar
• Hsu A, Card A, Lin SX, et al. Changes in postmenopausal hormone replacement therapy use among women with high cardiovascular risk. Am J Public Health 2009;99:2184–7
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Shoupe D, et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause 2015;22:391–401
   PubMed Web of Science ®Google Scholar
• Henderson VW, John JAS, Hodis HN, et al. Cognition, mood, and physiological concentrations of sex hormones in the early and late postmenopause. Proc Natl Acad Sci 2013;110:20290–5
   PubMed Web of Science ®Google Scholar
• Miller VM, Black D, Brinton E, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009;2:228–39
   PubMed Web of Science ®Google Scholar
• Wharton W, Gleason CE, Miller VM, et al. Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog). Brain Res 2013;1514:12–17
   PubMed Web of Science ®Google Scholar
• Wharton W, Gleason CE, Dowling NM, et al. The KEEPS-cognitive and affective study: baseline associations between vascular risk factors and cognition. J Alzheimers Dis 2014;40:331–41
   PubMed Web of Science ®Google Scholar
• Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. PLoS Med 2015;12:e1001833
   PubMed Web of Science ®Google Scholar
• Matyi JM, Rattinger GB, Schwartz S, et al. Lifetime estrogen exposure and cognition in late life: the Cache County Study. Menopause 2019;26:1366–74
   PubMed Web of Science ®Google Scholar
• Mosconi L, Rahman A, Diaz I, et al. Increased Alzheimer's risk during the menopause transition: a 3-year longitudinal brain imaging study. PLoS One 2018;13:e0207885
   PubMed Web of Science ®Google Scholar
• Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Mol Biol 2014;142:90–8
   PubMed Web of Science ®Google Scholar
• Hogervorst E, Bandelow S. Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. Maturitas 2010;66:56–71
   PubMed Web of Science ®Google Scholar
• Imtiaz B, Tuppurainen M, Rikkonen T, et al. Postmenopausal hormone therapy and Alzheimer disease: a prospective cohort study. Neurology 2017;88:1062–8
   PubMed Web of Science ®Google Scholar
• Song Y-j, Li S-r, Li X-w, et al. The effect of estrogen replacement therapy on Alzheimer's disease and Parkinson's disease in postmenopausal women: a meta-analysis. Frontiers Neurosci 2020;14:157
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651–62
   PubMed Web of Science ®Google Scholar
• Vaughan L, Espeland MA, Snively B, et al. The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). Brain Res 2013;1514:3–11
   PubMed Web of Science ®Google Scholar
• Espeland MA, Shumaker SA, Leng I, et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013;173:1429–36
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Controlled Clin Trials 1998;19:61–109
   PubMedGoogle Scholar
• Kim YJ, Brinton RD. Precision hormone therapy: gaps and opportunities. Gynecol Reprod Endocrinol Metab 2020;1:80–8
   Google Scholar
• Patel CJ, Burford B, Ioannidis JP. Assessment of vibration of effects due to model specification can demonstrate the instability of observational associations. J Clin Epidemiol 2015;68:1046–58
   PubMed Web of Science ®Google Scholar
• Brinton RD. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci 2008;31:529–37
   PubMed Web of Science ®Google Scholar
• Resnick SM, Espeland MA, Jaramillo SA, et al. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology 2009;72:135–42
   PubMed Web of Science ®Google Scholar
• Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, et al. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. BMJ 2019;364:l665
   PubMedGoogle Scholar
• Grodstein F, Chen J, Pollen DA, et al. Postmenopausal hormone therapy and cognitive function in healthy older women. J Am Geriatr Soc 2000;48:746–52
   PubMed Web of Science ®Google Scholar
• Kang JH, Weuve J, Grodstein F. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women. Neurology 2004;63:101–7
   PubMed Web of Science ®Google Scholar
• Riedel BC, Thompson PM, Brinton RD. Age, APOE and sex: triad of risk of Alzheimer's disease. J Steroid Biochem Mol Biol 2016;160:134–47
   PubMed Web of Science ®Google Scholar
• Wang Y, Brinton RD. Triad of risk for late onset Alzheimer’s: mitochondrial haplotype, APOE genotype and chromosomal sex. Front Aging Neurosci 2016;8:232
   PubMed Web of Science ®Google Scholar
• Mahoney-Sanchez L, Belaidi AA, Bush AI, et al. The complex role of apolipoprotein E in Alzheimer's Disease: an Overview and Update. J Mol Neurosci 2016;60:325–35
   PubMed Web of Science ®Google Scholar
• O'Donoghue MC, Murphy SE, Zamboni G, et al. APOE genotype and cognition in healthy individuals at risk of Alzheimer's disease: a review. Cortex 2018;104:103–23
   PubMed Web of Science ®Google Scholar
• Salameh TS, Rhea EM, Banks WA, et al. Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease. Exp Biol Med (Maywood) 2016;241:1676–83
   PubMed Web of Science ®Google Scholar
• Leduc V, Jasmin-Bélanger S, Poirier J. APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol Med 2010;16:469–77
   PubMed Web of Science ®Google Scholar
• Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007;298:1300–11
   PubMed Web of Science ®Google Scholar
• Mosconi L, Berti V, Quinn C, et al. Sex differences in Alzheimer risk: brain imaging of endocrine vs chronologic aging. Neurology 2017;89:1382–90
   PubMed Web of Science ®Google Scholar
• Wang Y, Mishra A, Brinton RD. Transitions in metabolic and immune systems from pre-menopause to post-menopause: implications for age-associated neurodegenerative diseases. F1000Res 2020;9:68
   Google Scholar
• Mosconi L, Nacmias B, Sorbi S, et al. Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004;75:370–6
   PubMed Web of Science ®Google Scholar
• Yaffe K, Haan M, Byers A, et al. Estrogen use, APOE, and cognitive decline: evidence of gene–environment interaction. Neurology 2000;54:1949–54
   PubMed Web of Science ®Google Scholar
• Kang JH, Grodstein F. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging 2012;33:1129–37
   PubMed Web of Science ®Google Scholar
• Ryan J, Carrière I, Scali J, et al. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C study. Neurology 2009;73:1729–37
   PubMed Web of Science ®Google Scholar
• Stone DJ, Rozovsky I, Morgan TE, et al. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer’s disease. J Neurosci 1998;18:3180–5
   PubMed Web of Science ®Google Scholar
• Srivastava RAK, Srivastava N, Averna M, et al. Estrogen up-regulates apolipoprotein E (ApoE) gene expression by increasing ApoE mRNA in the translating pool via the estrogen receptor alpha-mediated pathway. J Biol Chem 1997;272:33360–6
   PubMed Web of Science ®Google Scholar
• Karim R, Koc M, Rettberg JR, et al. Apolipoprotein E4 genotype in combination with poor metabolic profile is associated with reduced cognitive performance in healthy postmenopausal women: implications for late onset Alzheimer's disease. Menopause 2019;26:7–15
   PubMed Web of Science ®Google Scholar
• Xing Y, Jia J, Ji X, et al. Estrogen associated gene polymorphisms and their interactions in the progress of Alzheimer's disease. Prog Neurobiol 2013;111:53–74
   PubMed Web of Science ®Google Scholar
• Mann DM. The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev 1988;43:99–136
   PubMed Web of Science ®Google Scholar
• Chace C, Pang D, Weng C, et al. Variants in CYP17 and CYP19 cytochrome P450 genes are associated with onset of Alzheimer's disease in women with down syndrome. J Alzheimers Dis 2012;28:601–12
   PubMed Web of Science ®Google Scholar
• Hogervorst E, Williams J, Budge M, et al. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience 2000;101:485–512
   PubMed Web of Science ®Google Scholar
• Miller VM, Naftolin F, Asthana S, et al. The Kronos early estrogen prevention study (KEEPS): what have we learned? Menopause 2019;26:1071–84
   PubMed Web of Science ®Google Scholar
• Zhao L, Morgan TE, Mao Z, et al. Continuous versus cyclic progesterone exposure differentially regulates hippocampal gene expression and functional profiles. PLoS One 2012;7:e31267
   PubMed Web of Science ®Google Scholar
• Kantarci K, Lowe VJ, Lesnick TG, et al. Early postmenopausal transdermal 17β-estradiol therapy and amyloid-β deposition. J Alzheimers Dis 2016;53:547–56
   PubMed Web of Science ®Google Scholar
• Zhao L, Yao J, Mao Z, et al. 17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention. Neurobiol Aging 2011;32:1949–63
   PubMed Web of Science ®Google Scholar
• Kantarci K, Tosakulwong N, Lesnick TG, et al. Effects of hormone therapy on brain structure: a randomized controlled trial. Neurology 2016;87:887–96
   PubMed Web of Science ®Google Scholar
• Waring SC, Rocca WA, Petersen RC, et al. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999;52:965–70
   PubMed Web of Science ®Google Scholar
• Imtiaz B, Taipale H, Tanskanen A, et al. Risk of Alzheimer's disease among users of postmenopausal hormone therapy: a nationwide case-control study. Maturitas 2017;98:7–13
   PubMed Web of Science ®Google Scholar
• Schwartz J, Freeman R, Frishman W. Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women. J Clin Pharmacol 1995;35:314–29
   PubMed Web of Science ®Google Scholar
• Rocca WA, Bower JH, Maraganore D, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074–83
   PubMed Web of Science ®Google Scholar
• Maric-Bilkan C, Gilbert EL, Ryan MJ. Impact of ovarian function on cardiovascular health in women: focus on hypertension. Int J Women's Health 2014;6:131–9
   PubMedGoogle Scholar
• Rocca WA, Ulrich LG. Oophorectomy for whom and at what age? Primum non nocere. Maturitas 2012;71:1–2
   PubMed Web of Science ®Google Scholar
• Karvonen-Gutierrez CA, Park SK, Kim C. Diabetes and menopause. Curr Diab Rep 2016;16:20
   PubMed Web of Science ®Google Scholar
• Harman S, Brinton E, Cedars M, et al. KEEPS: the Kronos early estrogen prevention study. Climacteric 2005;8:3–12
   Google Scholar
• Wroolie TE, Kenna HA, Williams KE, et al. Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17β-estradiol versus conjugated equine estrogens. Am J Geriatr Psychiatry 2011;19:792–802
   PubMed Web of Science ®Google Scholar
• Silverman DH, Geist CL, Kenna HA, et al. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology 2011;36:502–13
   PubMed Web of Science ®Google Scholar
• Resnick SM, Espeland MA, An Y, et al. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J Clin Endocrinol Metab 2009;94:4152–61
   PubMed Web of Science ®Google Scholar
• Bove R, Secor E, Chibnik LB, et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2014;82:222–9
   PubMed Web of Science ®Google Scholar
• Zeydan B, Tosakulwong N, Schwarz CG, et al. Association of bilateral salpingo-oophorectomy before menopause onset with medial temporal lobe neurodegeneration. JAMA Neurol 2019;76:95–100
   PubMed Web of Science ®Google Scholar
• Imtiaz B, Tuppurainen M, Tiihonen M, et al. Oophorectomy, hysterectomy, and risk of Alzheimer's disease: a nationwide case-control study. J Alzheimers Dis 2014;42:575–81
   PubMed Web of Science ®Google Scholar
• Espeland MA, Brinton RD, Hugenschmidt C, et al. Impact of type 2 diabetes and postmenopausal hormone therapy on incidence of cognitive impairment in older women. Diabetes Care 2015;38:2316–24
   PubMed Web of Science ®Google Scholar
• Espeland MA, Brinton RD, Manson JE, et al. Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes. Neurology 2015;85:1131–8
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947–58
   PubMed Web of Science ®Google Scholar
• Jensen LB, Hilden J. Sociological and behavioural characteristics of perimenopausal women with an express attitude to hormone substitution therapy. Maturitas 1996;23:73–83
   PubMed Web of Science ®Google Scholar
• Progetto Menopausa Italia Study Group. General and medical factors associated with hormone replacement therapy among women attending menopause clinics in Italy. Menopause 2001;8:290–5
   PubMed Web of Science ®Google Scholar
• Lautenschlager N, Cupples L, Rao V, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: what is in store for the oldest old? Neurology 1996;46:641–50
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Cochrane BB, Hsia J, et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 2003;13:S78–S86
   PubMed Web of Science ®Google Scholar
• Henderson VW, John JAS, Hodis HN, et al. Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis. Neurology 2016;87:699–708
   PubMed Web of Science ®Google Scholar
• Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: women's Health Initiative Memory Study. JAMA 2004;291:2959–68
   PubMed Web of Science ®Google Scholar